Thrombotic Long-Term Consequences of SARS-CoV-2 Infection in Patients with Compensated Cirrhosis: A Propensity Score-Matched Analysis of a U.S. Database
Open Access
Abstract
Background: Cirrhosis causes an imbalance in the coagulation pathway and leads to a tendency for both bleeding and clotting. SARS-CoV-2 has been reported to be associated with a hypercoagulable state. This study examines SARS-CoV-2’s impact on hemostasis in compensated patients with cirrhosis. Methods: We analyzed the US Collaborative Network, which comprises 63 HCOs in the U.S.A. Compensated cirrhosis patients were split into two groups: SARS-CoV-2-positive and -negative. Patients’ baseline characteristics were used in a 1:1 propensity score-matched module to create comparable cohorts. We compared the risk of portal vein thrombosis (PVT), deep venous thrombosis (DVT), and pulmonary embolism (PE) at 6 months, and 1 and 3 years. Results: Of 330,521 patients, 27% tested positive and 73% remained negative. After PSM, both cohorts included 74,738 patients. Patients with SARS-CoV-2 had a higher rate of PVT compared to those without at 6 months (0.63% vs 0.5%, p < 0.05), 1 year (0.8% vs 0.6%, p < 0.05), and 3 years (1% vs. 0.7%, p < 0.05), a higher rate of DVT at 6 months (0.8% vs. 0.4%, p < 0.05), 1 year (1% vs. 0.5%, p < 0.05), and 3 years (1.4% vs. 0.8%, p < 0.05), and a higher rate of PE at 6 months (0.6% vs. 0.3%, p < 0.05), 1 year (0.7% vs. 0.4%, p < 0.05), and 3 years (1% vs. 0.6%, p < 0.05). Conclusions: The presence of SARS-CoV-2 infection in patients with compensated cirrhosis was associated with a higher rate of PVT, DVT, and PE at 6 months, and 1 and 3 years.Keywords
This publication has 50 references indexed in Scilit:
- Safety of DOACs in patients with Child‐Pugh Class C cirrhosis and atrial fibrillationJGH Open, 2024
- High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxisHeart & Lung, 2022
- Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19JAMA, 2021
- Risk of venous thromboembolism in a Swedish healthcare system during the COVID‐19 pandemic: A retrospective cross‐sectional studyJACEP Open, 2021
- Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 caseseClinicalMedicine, 2021
- Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern CaliforniaJAMA Internal Medicine, 2021
- Editorial commentary: Vascular injury in acute infections and COVID-19: everything old is new againTrends in Cardiovascular Medicine, 2021
- Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysisResearch and Practice in Thrombosis and Haemostasis, 2020
- Is Infection an Independent Risk Factor for Venous Thromboembolism? A Population-Based, Case-Control StudyThe American Journal of Medicine, 2018
- Changes in hemostasis in liver diseaseJournal of Hepatology, 2017